article thumbnail

$0 Copay Program Effectively Improved Glycemic Control | ADA 2025

Drug Topics

Researchers explored the impact of a $0 copay program on hemoglobin A1c levels in patients with type 2 diabetes who were also insured by Blue Cross and Blue Shield of Louisiana.

Insurance 341
article thumbnail

Obesity Medication Use Remains Low Among Children | ADA 2025

Drug Topics

Despite a high prevalence of childhood and youth-aged obesity, the use of medications for treating obesity is persistently low among children and young adults (YA), according to an abstract presented at the American Diabetes Association’s 85th Scientific Sessions, held in Chicago, Illinois, from June 20-23, 2025. Accessed June 25, 2025.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Dispensing Leadership: Be Easy to Do Business With

Drug Topics

From prior authorizations to insurance roadblocks, each decision a pharmacy makes can either ease or complicate that experience. Whether it's trying to check out at a crowded store or navigating complex prescription issues, barriers frustrate people—and pharmacies are no different.

article thumbnail

Q&A: Pharmacist Highlights Challenges in Vaccine Information Navigation Amid Changing Recommendations

Drug Topics

This schedule also helped dictate insurance coverage of those recommended vaccines. Drug Topics: How do ACIP recommendations affect broader aspects of vaccine access and utilization, such as insurance reimbursement or public health programs?

Vaccines 247
article thumbnail

Health care practitioners sound the alarm on middlemen-imposed barriers to patient care, need for policy change

PhRMA

Specifically, HCPs raised concerns over how pharmacy benefit managers (PBMs) and insurers inappropriately use utilization management tools, like prior authorization, to deny or delay care, ultimately harming the patient and impacting patient access to care.

article thumbnail

STAT+: DOJ probes device maker whose test resulted in lucrative diagnoses for UnitedHealth and other insurers

STAT

The Department of Justice is investigating Semler Scientific for possible violations of a federal anti-fraud law related to its marketing of a product known as QuantaFlo, a test used in the diagnosis of peripheral artery disease by UnitedHealth Group and other large insurers.   The SEC filing states that on Feb.

Insurance 134
article thumbnail

A closer look at how health care consolidation drives up patient costs, creates barriers to care

PhRMA

Half of every dollar spent on medicines goes to entities that don’t make medicine—like pharmacy benefit managers (PBMs) and insurers who are aggressively consolidating their control over health care and hospitals, clinics and for-profit pharmacies in the 340B markup program.

Insurance 263